Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Related Articles by Review for PubMed (Select 16116154)

1.

Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.

Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK.

J Clin Oncol. 2005 Sep 20;23(27):6474-80. Epub 2005 Aug 22.

2.

Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.

Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M.

J Clin Oncol. 1998 Oct;16(10):3286-94. Review.

PMID:
9779703
3.

Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.

George RE, Variend S, Cullinane C, Cotterill SJ, McGuckin AG, Ellershaw C, Lunec J, Pearson AD; United Kingdom Children Cancer Study Group.

Med Pediatr Oncol. 2001 Jan;36(1):169-76. Review.

PMID:
11464876
4.

[Management strategy in neuroblastoma].

Balwierz W.

Przegl Lek. 2004;61 Suppl 2:3-8. Review. Polish.

PMID:
15686038
5.

Childhood and adolescent large-cell lymphoma (LCL): a review of the Children's Cancer Group experience.

Cairo MS, Sposto R, Hoover-Regan M, Meadows AT, Anderson JR, Siegel SE, Kadin ME, Kjeldsberg CR, Wilson JF, Perkins SL, Lones MA, Morris E, Finlay JL.

Am J Hematol. 2003 Jan;72(1):53-63. Review.

PMID:
12508269
6.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

7.

Fibrolamellar hepatocellular carcinoma in children and adolescents.

Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Qu W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC.

Cancer. 2003 Apr 15;97(8):2006-12. Review.

8.

Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.

Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B.

BMC Cancer. 2007 May 25;7:89. Review.

9.

Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies.

van Noesel MM, Hählen K, Hakvoort-Cammel FG, Egeler RM.

Cancer. 1997 Sep 1;80(5):834-43. Review.

PMID:
9307181
10.

[Neuroblastoma].

Sawada T, Komatsu H, Shirai C, Yamamoto S, Ishiwari K, Ishida H, Ohmizono Y, Matsumura T.

Gan To Kagaku Ryoho. 1995 Jan;22(1):28-36. Review. Japanese.

PMID:
7826075
11.

Risk-based management: current concepts of treating malignant solid tumors of childhood.

Grosfeld JL.

J Am Coll Surg. 1999 Oct;189(4):407-25. Review.

PMID:
10509467
12.

A comparison of current neuroblastoma chemotherapeutics.

Castel V, Cañete A.

Expert Opin Pharmacother. 2004 Jan;5(1):71-80. Review.

PMID:
14680437
13.

Favorable histology, MYCN-amplified 4S neonatal neuroblastoma.

Chan EL, Harris RE, Emery KH, Gelfand MJ, Collins MH, Gruppo RA.

Pediatr Blood Cancer. 2007 Apr;48(4):479-82. Review.

PMID:
16333837
14.

Overview of current treatment of neuroblastoma.

Philip T.

Am J Pediatr Hematol Oncol. 1992 May;14(2):97-102. Review.

PMID:
1382390
15.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
16.

[Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use].

Pérel Y, Valteau-Couanet D, Michon J, Lavrand F, Coze C, Bergeron C, Notz A, Plantaz D, Chastagner P, Bernard F, Thomas C, Rubie H.

Arch Pediatr. 2004 Jul;11(7):834-42. Review. French.

PMID:
15234382
17.

Current biologic and therapeutic implications in the surgery of neuroblastoma.

Azizkhan RG, Haase GM.

Semin Surg Oncol. 1993 Nov-Dec;9(6):493-501. Review.

PMID:
8284568
18.
19.

Neuroblastoma in the first year of life: clinical and biologic factors influencing outcome.

Grosfeld JL, Rescorla FJ, West KW, Goldman J.

Semin Pediatr Surg. 1993 Feb;2(1):37-46. Review.

PMID:
8062021
20.

Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma.

Matthay KK.

Pediatr Transplant. 1999;3 Suppl 1:72-7. Review.

PMID:
10587975
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk